There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dicerna Pharma (DRNA – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments.
Dicerna Pharma (DRNA)
Evercore ISI analyst Umer Raffat maintained a Buy rating on Dicerna Pharma yesterday. The company’s shares closed last Monday at $14.47.
According to TipRanks.com, Raffat is a 1-star analyst with an average return of -4.4% and a 50.0% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Dova Pharmaceuticals Inc, and Jazz Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $21.80 average price target, which is a 54.6% upside from current levels. In a report issued on August 8, Cowen & Co. also maintained a Buy rating on the stock.
Bluebird Bio (BLUE)
Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Bluebird Bio yesterday and set a price target of $172. The company’s shares closed last Monday at $118.82.
“We are updating our model following BLUE’s 2Q19 earnings release – no change to PT ($172, OP). Within, we provide an overview on 2H19’s remaining stock-moving events as well as an outlook on 2020.”
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.8% and a 50.8% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Mirum Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $149.88, which is a 27.5% upside from current levels. In a report issued on August 1, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.